Earnings Charges: Social media users have been discussing Biogen's recent pre-announcement of significant in-process R&D charges expected to hit adjusted earnings in the second and third quarters. Analysts noted these costs stem from ongoing business development deals and could pressure near-term results by roughly a dollar per share. Observers highlighted how such moves reflect continued investment in the pipeline amid a competitive biotech landscape.
Analyst Moves: A notable upgrade from Needham, raising the price target slightly to $256 with a buy rating, drew attention in recent conversations. Market commentators also included the stock in broader 2026 outlooks alongside other major names, citing potential opportunities. Discussions emphasized the firm's strategic acquisitions without speculating on valuation levels.
Market Sentiment: Overall chatter reflected a blend of scrutiny over quarterly impacts and interest in forward-looking developments. Participants pointed to the company's hiring practices and pipeline focus as additional talking points in the biotech sector.
Note: This discussion summary was generated from an AI condensation of post data.
Biogen Insider Trading Activity
Biogen insiders have traded $BIIB stock on the open market 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:
- PRIYA SINGHAL (Head of Development) has made 0 purchases and 2 sales selling 3,408 shares for an estimated $665,664.
- NICOLE MURPHY (Head of Pharm Ops and Tech) purchased 3 shares for an estimated $585
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Biogen Revenue
Biogen had revenues of $2.5B in Q1 2026. This is an increase of 1.93% from the same period in the prior year.
You can track BIIB financials on Quiver Quantitative's BIIB stock page.
You can access data on BIIB stock through the Quiver Quantitative API.
Biogen Congressional Stock Trading
Members of Congress have traded $BIIB stock 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 06/05, 01/30 and 0 sales.
- REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 3 times. They made 3 purchases worth up to $130,000 on 05/12, 05/11 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Biogen Hedge Fund Activity
We have seen 464 institutional investors add shares of Biogen stock to their portfolio, and 343 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 3,381,678 shares (+35.9%) to their portfolio in Q1 2026, for an estimated $619,963,027
- POINT72 ASSET MANAGEMENT, L.P. removed 2,003,575 shares (-71.2%) from their portfolio in Q1 2026, for an estimated $367,315,404
- BLACKROCK, INC. added 1,163,231 shares (+7.9%) to their portfolio in Q1 2026, for an estimated $213,255,139
- MILLENNIUM MANAGEMENT LLC removed 1,031,622 shares (-91.7%) from their portfolio in Q1 2026, for an estimated $189,127,261
- BARCLAYS PLC removed 753,533 shares (-57.7%) from their portfolio in Q1 2026, for an estimated $138,145,204
- WELLINGTON MANAGEMENT GROUP LLP removed 589,628 shares (-16.6%) from their portfolio in Q1 2026, for an estimated $108,096,501
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 521,385 shares (-78.8%) from their portfolio in Q1 2026, for an estimated $95,585,512
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Biogen Analyst Ratings
Wall Street analysts have issued reports on $BIIB in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 06/29/2026
- Evercore ISI Group issued a "Outperform" rating on 05/15/2026
- Guggenheim issued a "Buy" rating on 04/30/2026
- Oppenheimer issued a "Outperform" rating on 01/30/2026
To track analyst ratings and price targets for Biogen, check out Quiver Quantitative's $BIIB forecast page.
Biogen Price Targets
Multiple analysts have issued price targets for $BIIB recently. We have seen 19 analysts offer price targets for $BIIB in the last 6 months, with a median target of $225.0.
Here are some recent targets:
- Ami Fadia from Needham set a target price of $256.0 on 06/29/2026
- Matthew Harrison from Morgan Stanley set a target price of $224.0 on 06/18/2026
- Salim Syed from Mizuho set a target price of $221.0 on 06/15/2026
- Brian Abrahams from RBC Capital set a target price of $227.0 on 05/27/2026
- David Amsellem from Piper Sandler set a target price of $225.0 on 05/15/2026
- Geoff Meacham from Citigroup set a target price of $200.0 on 05/01/2026
- Yatin Suneja from Guggenheim set a target price of $260.0 on 04/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
